Sugar Editorial Picks
Feb 21, 2007 -
Bob Greene, Oprah's trainer and author of The Best Life Diet is getting several lucky people in shape for The Best Life Weight Loss Challenge and you can follow along and get in shape too!
Before you get started, Bob wants you to ask yourself these questions:
Why am I overweight?
Rather than "I don't have time to make healthy food" or "I have to eat out a lot," recognize the feelings that lead you to overeat.
- 0 Comments
Other Search Results
Apr 24, 2009 -
I'm a huge fan of Shiva Rea and all her yoga videos, so I was thrilled to hear she had a new video called Surf Yoga Soul ($15). You don't have to be a surfer to enjoy this video, since it focuses on creative movements that open your body and heart, and strengthen your muscles and mind, to help you "surf the power of the life force within you." OK, that might be a little cheesy, but the DVD is great fun.
- 5 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Recommended Exercise Method...
- Exercise's Effects on the H...
- Exercise's Effects on Diabe...
- Exercise's Effects on Bones...
- Exercise's Effects on the L...
- Exercise's Effects on Weigh...
- Exercise's Effects on Other...
- Complications
- Motivation
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Chronic Conditions and Exercise:
- A new study found that aerobic and resistance training significantly reduced fatigue in men undergoing radiation treatments for prostate cancer. Fatigue is a common side effect of such treatments.
- Doctors at the Mayo Clinic found that exercise improves the physical and emotional well-being of patients with Alzheimer's disease. The patients exercised for as little as 60 minutes each week.
- 1 Comment
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Risk Factors
- Causes
- Prognosis
- Diagnosis
- Treatment
- Medications
- Other Treatments
- Therapy and Lifestyle Chang...
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Approval
In 2007, the FDA approved risperidone (Risperdal) for short-term treatment of manic or mixed episodes of bipolar I disorder in children ages 10 - 17. Risperidone (an atypical antipsychotic) and lithium (a mood stabilizer) are the two drugs currently approved for treating pediatric patients with bipolar disorder.
Drug Warnings
- Olanzapine (Zyprexa, Symbex) causes a greater risk for high blood sugar than other atypical antipsychotics, according to updated information added to the drug’s warning label.
- 1 Comment
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Risk Factors
- Complications of Depression...
- Diagnosis
- Treatment
- Antidepressants and Drug Tr...
- Psychotherapy
- Other Treatments
- Lifestyle Changes
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Approval
In 2007, the Food and Drug Administration (FDA) approved the atypical antipsychotic drug aripiprazole (Abilify) for treatment of major depression in adults. Aripiprazole is used for treatment of schizophrenia and bipolar disorder. For depression, it is used in combination with antidepressant drug therapy.
- 5 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Risk Factors
- Complications
- Diagnosis
- Treatment
- Medications
- Other Treatments
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Approval
In 2007, duloxetine (Cymbalta) was approved for treatment of generalized anxiety disorder. Duloxetine is a dual inhibitor antidepressant.
Anxiety Disorders Under-Recognized and Under-Treated
About 41% of patients with an anxiety disorder do not receive any treatment, indicates a 2007 study in the Annals of Internal Medicine.
- 1 Comment
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Symptoms
- Causes
- Prognosis
- Risk Factors
- Diagnosis
- Treatment
- Quick-Relief Medications...
- Long-Term Relief Medication...
- Other Treatments
- Managing Asthma
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Warning
In 2007, the FDA requested the manufacturers of omalizumab (Xolair) to include a “boxed warning” emphasizing that this drug may cause a severe and life-threatening allergic reaction (anaphylaxis). Omalizumab is approved for patients who have moderate-to-severe asthma related to allergies and whose symptoms are not controlled by inhaled corticosteroids. It is given by injection in a doctor’s office every 2 - 4 weeks.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Prognosis
- Risk Factors
- Symptoms
- Diagnosis
- Treatment
- Quick-Relief Medications...
- Long-Term Relief Medication...
- Other Treatments
- Managing Asthma
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Warning
In 2007, the FDA requested the manufacturers of omalizumab (Xolair) to include a “boxed warning” emphasizing that this drug may cause a severe and life-threatening allergic reaction (anaphylaxis). Health care providers need to carefully observe patients for 2 hours after they receive an omalizumab injection. However, because an allergic reaction can occur up to 24 hours after the injection, patients need to know the signs and symptoms of anaphylaxis and how to self-administer emergency treatment.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- The Body's Response
- Complications
- Conditions with Similar Sym...
- Treatment
- Risk Factors
- Lifestyle Changes
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
- Some people are pre-programmed for a heightened response to stress by conditions in the womb. Pregnant women under stress who eat a diet high in protein and low in carbohydrates have babies with higher cortisol levels. Later on, these levels increase in response to stress.
- The impact of stress on the heart and circulation system is becoming more clear.
- 0 Comments
Oct 08, 2008 -
Overview
- Signs and Symptoms
- What Causes It?
- Risk Factors
- What to Expect at Your Provider's Office
- Preventive Care
- Treatment Options
- Other Considerations
- Supporting Research
HEALTH GUIDE REFERENCE FROM A.D.A.M
Attention deficit hyperactivity disorder (ADHD) is a developmental disorder characterized by inattention, hyperactivity, and impulsivity. It is the most commonly diagnosed behavioral disorder of childhood, affecting between 3 - 5% of school-aged children. Although many people occasionally have difficulty sitting still, paying attention, or controlling impulsive behavior, people with ADHD find that these symptoms greatly interfere with everyday life.
- 0 Comments